EPCAM and breast carcinoma: Breast cancer patients displayed a significant enrichment of ROR1- (cancer: median 0.1, 95% CI [0.1–1.42]; healthy: median 0, 95% CI [0.004–0.19]), ROR2- (cancer: median 11.55, 95% CI [9.89–18.61]; healthy: median 5.7, 95% CI [4.36–9.35]) as well as EpCAM-positive lEVs (cancer: median 0.9, 95% CI [1.45–7.30]; healthy: median 0.1, 95% CI [0.12–1.28]) compared to healthy controls (Fig. 6D + E).